Abstract:Atherosclerosis is the leading cause of death in western countries. Lipoprotein metabolism is closely related with the disease. ApoB-containing lipoproteins (BLp) are atherogenic particles, while, high density lipoproteins (HDL) are anti-atherogenic. Phospholipids Transfer Protein (PLTP) activity has important impact on BLp and HDL homeostasis. Animal studies, including general knock out (KO) and transgenic approaches, have shown pro-atherogenic properties for PLTP. However, the tissue specific function of PLTP remains mostly unknown. To address the impact of liver-specific expression of PLTP on lipoprotein metabolism, we have created two mouse models which either express PLTP specifically in the liver on a PLTP-null background or do not express PLTP in the liver (liver-specific PLTP KO) in a wild type background. In both models, our findings show that liver-specific PLTP is responsible for 25-30% of total plasma PLTP activity. Moreover, liver-specific PLTP expression model shows a remarkable increase in plasma levels of BLp, whereas liver-specific PLTP KO mice show significant reduction of BLp in plasma in compare to control group. These results further show the significant contribution of PLTP in BLp production. We also found that HDL levels are slightly increased in the first model, while in liver-specific PLTP KO animals HDL levels are significantly decreased. In order to unravel the mechanism, we evaluated the apoB and triglyceride production rates after blocking the clearance of the particles. We found that liver-specific PLTP increases apoB (both apo48 and apoB100) and triglyceride (TG) secretion rates. Additionally, the study of the hepatocyte microsomal luminal content lipidation in the first model showed that in the presence of PLTP BLp lipidation, which reflects as higher level of TG in microsomal luminal content, is significantly higher than the control group. Our results indicate that liver-generated PLTP promotes atherogenic lipoprotein production and provides a rationale for liver-specific PLTP inhibition as a therapeutical approach for the treatment of atherosclerosis.

High Plasma Phospholipid Transfer Protein Levels As a Risk Factor for Coronary Artery Disease

Plasma PLTP Activity is Inversely Associated with HDL-C Levels

Pltp Activity is A Risk Factor for Subsequent Cardiovascular Events in Cad Patients under Statin Therapy: the Atherogene Study

Phospholipid transfer protein in hemodialysis patients.

Elevated Baseline Plasma Phospholipid Protein (PLTP) Levels Are an Independent Predictor of Long-Term All-Cause Mortality in Patients with Diabetes Mellitus and Known or Suspected Coronary Artery Disease.

PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity

Serum Phospholipid Transfer Protein Activity after a High Fat Meal in Patients with Insulin-Treated Type 2 Diabetes

The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis

Increased Atherosclerotic Lesions in ApoE Mice with Plasma Phospholipid Transfer Protein Overexpression

Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels.

High PLTP Activity is Associated with Depressed Left Ventricular Systolic Function.

Macrophage Phospholipid Transfer Protein Contributes Significantly To Total Plasma Phospholipid Transfer Activity And Its Deficiency Leads To Diminished Atherosclerotic Lesion Development

Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate

Phospholipid Transfer Protein Destabilizes Mouse Atherosclerotic Plaque.

Phospholipid Transfer Protein Deficiency Protects Circulating Lipoproteins from Oxidation Due to the Enhanced Accumulation of Vitamin E

The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis D.M. is supported by a grant from the Philippe Foundation. Published, JLR Papers in Press, November 20, 2008.

Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis

Impact of Phospholipid Transfer Protein in Lipid Metabolism and Cardiovascular Diseases

Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis

PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity

Abstract 330: Liver-Specific Phospholipids Transfer Protein Activity Has Significant Contribution in Hepatocyte Apob-Containing Lipoprotein Production and in Plasma Lipoprotein Metabolism